Indeed, the VGVAPG treatment of CD4+ T-cells increased the percentage of cells expressing IL-4 in COPD patients, and these effects were inhibited in the presence of analogous peptide antagonizing EP/elastin receptor (S-gal) interactions. This evidence concerns the gene CD4 and chronic obstructive pulmonary disease.